Amgen developing intracellular therapies with Elasmogen, Feldan

Elasmogen Ltd. (Aberdeen, U.K.) and Feldan Therapeutics Inc. (Quebec, Quebec) partnered with Amgen Inc. (NASDAQ:AMGN) to develop candidates targeting two undisclosed intracellular targets.

The companies will use Feldan's Shuttle platform in combination with Elasmogen's soloMER technology. Feldan's Shuttle uses a peptide-based delivery system to introduce proteins into cells. soloMER biologics are 9% of the size of an antibody, and are derived from variable new-antigen receptors (VNARS)...